Solu Therapeutics

Solu Therapeutics is a private, clinical-stage biotech developing a groundbreaking platform that conjugates bifunctional small molecules to antibodies, creating novel drug classes like CyTACs and TicTACs. This approach allows targeting of previously inaccessible cell surface proteins, such as GPCRs, with enhanced specificity and pharmacokinetics. The company's lead asset, STX-0712, is in Phase 1 for chronic myelomonocytic leukemia (CMML), with a pipeline spanning oncology, immunology, and pain. Backed by experienced leadership and venture capital, Solu leverages an exclusive license from GSK and aims to rapidly advance programs from concept to clinic.

Proprietary platform creating bifunctional therapeutics (CyTACs and TicTACs) that link potent small molecule binders (targeting GPCRs, ion channels) to effector antibodies via a specialized linker, enabling targeting of previously undruggable cell surface proteins.

Solu operates in the competitive field of bifunctional and targeted protein degradation therapeutics, facing indirect competition from companies developing PROTACs, molecular glues, antibody-drug conjugates (ADCs), and bispecific antibodies. Its unique niche is the specific targeting of cell surface proteins with small molecule-antibody conjugates, differentiating it from intracellular degraders and traditional biologics.